| Age, median (range) | 60 (19-73) |
| Gender, male | 83 (58%) |
| Baseline disease | AML 44 (31%) |
| MDS 33 (23%) | |
| NHL/HL 27 (19%)/ 9 (6%) | |
| MM 5 (3.5%) | |
| Other 24 (17.5%) | |
| Source, Peripheral blood | 127 (89%) |
| Donor type | Unrelated identical 47 (33%) |
| Related identical 42 (30%) | |
| Haploidentical 32 (22%) | |
| Unrelated mismatch 21 (15%) | |
| CMV status −/− | 8 (5.6%) |
| CD34/kg E6, median (range) | 6 (1.3-8.9) |
| GvHD prophylaxis | PT-Cy 90 (63%) |
| Sirolimus-Tacrolimus 19 (13.5%) | |
| Tacrolimus-based 19 (13.5%) | |
| Cyclosporine-based 14 (10%) | |
| Prior GvHD | aGvHD II-IV 38 (27%) cGvHD moderate-severe 25 (17%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.